If the clinical scale is so bad, then it might not be the best ending point to show efficacy of the drug, that can balance the side effects, expensive price and changes in diagnostic setup of AD. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients. Think further and longer studies will be needed to demonstrate sufficient efficacy that will make a meaningful difference for the patients and relatives.